Amneal Pharmaceuticals, Inc. 4

Director Paul M. Meister had 48,747 RSUs vest into Class A Common Stock and received a new equity grant of 30,837 Class A shares of Amneal Pharmaceuticals, Inc., with no open-market purchases or sales reported.

On May 7, 2026, Paul M. Meister converted 48,747 previously granted restricted stock units into an equivalent number of Amneal Pharmaceuticals, Inc. Class A Common shares (coded as an “M” transaction with an acquisition of 48,747 shares and a corresponding reduction of 48,747 RSUs), with no price reported, implying a compensation-related vesting rather than an open-market trade. Separately, on May 6, 2026, he received a new grant of 30,837 Class A Common shares (or RSUs for such shares) at no stated cost, increasing his direct ownership to 832,800 shares. These transactions reflect routine equity compensation and vesting activity rather than discretionary buying or selling in the open market.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

sec

Accession

0001628280-26-032907

Alert Tier

5